B. Metzler seel. Sohn & Co. Holding AG Purchases New Holdings in Insmed Incorporated (NASDAQ:INSM)

B. Metzler seel. Sohn & Co. Holding AG bought a new stake in Insmed Incorporated (NASDAQ:INSM - Free Report) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 10,510 shares of the biopharmaceutical company's stock, valued at approximately $767,000.

Several other institutional investors have also modified their holdings of the company. Darwin Global Management Ltd. acquired a new position in shares of Insmed during the second quarter valued at $237,076,000. Clearbridge Investments LLC grew its holdings in Insmed by 76.8% during the second quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company's stock worth $110,212,000 after acquiring an additional 714,539 shares during the period. Fiera Capital Corp acquired a new stake in Insmed in the 2nd quarter valued at about $40,570,000. Farallon Capital Management LLC bought a new stake in shares of Insmed in the 2nd quarter worth approximately $38,056,000. Finally, Fred Alger Management LLC acquired a new stake in shares of Insmed during the 2nd quarter valued at $33,404,000.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on INSM. JPMorgan Chase & Co. boosted their price target on shares of Insmed from $74.00 to $83.00 and gave the company an "overweight" rating in a report on Friday. HC Wainwright restated a "buy" rating and issued a $90.00 price objective on shares of Insmed in a report on Friday, November 1st. StockNews.com downgraded shares of Insmed from a "hold" rating to a "sell" rating in a research report on Friday, August 9th. Truist Financial reiterated a "buy" rating and issued a $105.00 price objective (up from $100.00) on shares of Insmed in a report on Friday, November 1st. Finally, Stifel Nicolaus increased their price objective on Insmed from $74.00 to $88.00 and gave the company a "buy" rating in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $83.67.

Insmed Stock Performance

Shares of NASDAQ:INSM traded down $0.66 during trading on Friday, hitting $73.15. 1,756,992 shares of the stock were exchanged, compared to its average volume of 1,646,243. The company's fifty day simple moving average is $72.04 and its 200-day simple moving average is $66.31. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The company has a market capitalization of $13.09 billion, a price-to-earnings ratio of -13.18 and a beta of 1.12. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $80.53.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. The business's quarterly revenue was up 18.1% on a year-over-year basis. During the same period last year, the company posted ($1.10) EPS. Sell-side analysts expect that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In other news, insider Michael Alexander Smith sold 27,871 shares of Insmed stock in a transaction on Friday, September 13th. The shares were sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the transaction, the insider now directly owns 67,856 shares of the company's stock, valued at $5,045,093.60. This trade represents a 29.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Martina M.D. Flammer sold 13,436 shares of the firm's stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the sale, the insider now directly owns 106,134 shares in the company, valued at $7,951,559.28. The trade was a 11.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 78,882 shares of company stock worth $5,765,446 over the last three months. Company insiders own 4.60% of the company's stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.